Maze Therapeutics (MAZE) Stock Forecast & Price Target
Score
Maze Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 13 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
14 analysts cover MAZE.
Is Maze Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Maze Therapeutics, Inc., 14 rate it a buy (1 strong buy and 13 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The MAZE consensus label is Buy, beside 14 buy-side ratings and 0 sell-side ratings.
the Maze Therapeutics, Inc. closes with 14 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Maze Therapeutics, Inc. forecast
Most of the MAZE coverage agrees: 14 of 14 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
MAZE targets have not moved much: $75.00 recently, $75.00 across the quarter.
MAZE coverage is thin at 14 analysts, and one revision moves the average.
Maze Therapeutics, Inc. forecast questions
What is the MAZE price target?
No average price target is on file for MAZE.
Is Maze Therapeutics, Inc. a buy or sell?
Of the 14 analysts covering Maze Therapeutics, Inc., 14 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for MAZE is 14 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Maze Therapeutics, Inc.?
No EPS estimate for the next two fiscal years is on file for Maze Therapeutics, Inc..
What is the revenue estimate for Maze Therapeutics, Inc.?
No revenue estimate for the next two fiscal years is on file for Maze Therapeutics, Inc..
How many analysts cover MAZE?
14 analysts cover MAZE. Their consensus on MAZE is Buy, across those 14.